Aflibercept is the most recently approved vascular endothelial growth factor (anti-VEGF) inhibitor for the management of diabetic macular edema and diabetic retinopathy. The purpose of this article is to review the efficacy and safety of aflibercept in the management of diabetic eye complications and to describe its place in therapy. Anti-VEGF agents have been noted in clinical trials to be superior to laser photocoagulation, the standard therapy (P < .0001, P ≤ .0085, respectively). Aflibercept has been comparatively studied with other anti-VEGF agents, namely, bevacizumab and ranibizumab, and noted to be equally efficacious and safe in patients with mild visual acuity loss (P > .50). However, in the treatment of patients with diabetic macular edema having moderate to severe visual acuity loss, aflibercept outperformed the other 2 anti-VEGF agents (aflibercept vs bevacizumab, P < .001; aflibercept vs ranibizumab, P = .003). However, additional studies are needed to fully appreciate the long-term safety and efficacy of aflibercept and the anti-VEGF therapy class.
Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. Atlanta, GA: US Department of Health and Human Services; 2014.
National Eye Institute, National Institutes of Health. Facts about Diabetic Eye Disease. New York City, NY: National Institutes of Health. Web sit. https://nei.nih.gov/health/diabetic/retinopathy. Reviewed September, 2015. Accessed April 29, 2016.
4.
Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1985;103(12):1796–1806.
5.
MartinDFMaguireMG. Treatment choice for diabetic macular edema. N Engl J Med. 2015;372(13):1260–1261.
6.
The Diabetic Retinopathy Clinical Research Network, WellsJAGlassmanARAyalaAR. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203.
7.
MarozasLMFortPE. Diabetic retinopathy: update on prevention techniques, present therapies, and new leads. US Ophthalmic Rev. 2014;7(1):54–58.
8.
Diabetic Retinopathy Clinical Research Network, ElmanMJAielloLPBeckRW. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077.e35.
9.
ArevaloJFLasaveAFWuL.; Pan-American Collaborative Retina Study Group (PACORES). Intravitreal bevacizumab plus grid laser photocoagulation or intravitreal bevacizumab or grid laser photocoagulation for diffuse diabetic macular edema: results of the Pan-American Collaborative Retina Study Group at 24 months. Retina. 2013;33(2):403–413.
10.
KorobelnikJFDoDVSchmidt-ErfurthU. Intravitreal aflibercept for diabetic macular edema. Ophthalmology. 2014;121(11):2247–2254.
11.
BrownDMNguyenQDMarcusDM; RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36 months results from two phase III trials: RISE and RIDE. Ophthalmology. 2013;120(10):2013–2022.
12.
RajendramRFraser-BellSKainesA. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol. 2012;130(8):972–979.
13.
VentricePLeporiniCAloeJF. Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases. J Pharmacol Pharmacother. 2013;4(suppl 1):s38–s42.
14.
MoroneyJWSoodAKColemanRL. Aflibercept in epithelial ovarian carcinoma. Future Oncol. 2009;5(5):591–600.
15.
SharmaYRTripathyKVenkateshP. Aflibercept—how does it compare with other anti-VEGF drugs. J Clin Pharmacol. 2014;1(3):1016.
16.
SelimKMSahanDMuhittinT. Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy. Indian J Ophthalmol. 2010;58(5):375–379.
17.
YangLPMcKeageK. Intravitreal aflibercept (Eylea®): a review of its use in patients with macular oedema secondary to central retinal vein occlusion. Drugs Aging. 2014;31(5):395–404.
18.
CiullaTAAmadorAGZinmanB. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care. 2003;26(9):2653–2664.
Del AmoEMUrttiA. Rabbit as an animal model for intravitreal pharmacokinetics: clinical predictability and quality of the published data. Exp Eye Res. 2015;137:111–124. Web site. http://www.sciencedirect.com/science/article/pii/S0014483515001451. Accessed April 29, 2016.
21.
ChristoforidisJBWilliamsMMKothandaramanS. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT. Curr Eye Res. 2012;37(12):1171–1174.
22.
KrohneTUEterNHolzFG. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008;146(4):508–512.
23.
MauriceDMMishimaS. Ocular pharmacokinetics. In: SearsMI, ed. Pharmacology of the Eye. New York, NY: Springer-Verlag; 1984:19–116.
24.
BrowningDJKaiserPKRosenfeldPJ. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?Am J Ophthalmol. 2012;154(2):222–226.
StewartMW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol. 2014;7(2):167–180: Web site. http://informahealthcare.com/doi/abs/10.1586/17512433.2014.884458. Informa Health Care. 2014; 167-180. Accessed April 29, 2016.
27.
DoDVSchmidt-ErfurthU. The DA VINCI study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology. 2011;118(9):1819–1826.
28.
AveryRLCastellarinAASteinleNC. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br J Ophthalmol. 2014;98(12):1636–1641.
29.
RegnierSMalcolmWAllenF. Efficacy of anti-VEGF and laser photocoagulation in the treatment of visual impairment due to diabetic macular edema: a systematic review and network meta-analysis. PLoS One. 2014;9(7):e102309.
30.
OguraYTerasakiHGomiF. Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. Br J Ophthalmol. 2015;99(1):92–97.
31.
HeierJSBrownDMChongV; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–2548.
32.
BoyerDHeierJBrownDM. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024–1032.
33.
BrownDMHeierJSClarkWL. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. Am J Ophthalmol. 2013;155(3):429–437.e7.
34.
HolzFGRoiderJOguraY. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97(3):278–284.
35.
FerraraNDamicoLShamsN. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006;26(8):859–870.
36.
Lucentis (Ranibizumab). Red book online [Internet database]. Greenwood Village, CO: Thompson Micromedex. Updated periodically.
37.
RegnierSAMalcolmWHaigJ. Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic edema: a UK healthcare perspective. Clinicoecon Outcomes Res. 2015;7:235–247.
38.
HurleySFMatthewsJPGuymerRH. Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration. Cost Eff Resour Alloc. 2008;6:12.
